volume 2, issue 8, PS603 2007
DOI: 10.1097/01.jto.0000283747.85598.3d
View full text
|
|
Share

Abstract: Background: Patients who have progressed on first-line chemotherapy for mesothelioma have few treatment options, and there are no approved second-line therapies. Preclinical data suggest a therapeutic role for targeting both VEGF and EGFR in this disease. We hypothesized that combination molecular therapy targeting the EGFR pathway and tumor angiogenesis may be more effective than inhibiting either pathway by itself. We therefore conducted a multi-center phase II trial of erlotinib plus bevacizumab in previous…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
1
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals